)
Gedeon Richter (RICHTER) investor relations material
Gedeon Richter Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q1–Q3 Pharma revenue grew 11.7% at CER and Clean EBIT rose 25% at CER; reported revenue increased 2.6% to HUF 686.5bn amid ~9ppt FX drag.
Net profit rose 7.1% to HUF 174.9bn, while free cash flow reached a record HUF 223.4bn, up 12% YoY.
Financial highlights
Pharma gross profit, net of restructuring charges, rose 2.5% to HUF 474.5bn; gross margin eased 0.1ppt to 69.1%.
Pharma Clean EBIT increased 7.9% reported to HUF 229.9bn; reported EBIT rose 6.0% to HUF 216.8bn.
Pharma operating expenses declined 3% YoY in Q1–Q3: R&D rose 3%, S&M fell 7% and G&A increased 2%.
EPS rose 7.1% to HUF 956; net financial expenses remained broadly unchanged at HUF 9.5bn.
Outlook and guidance
FY2026 Pharma revenue growth guidance upgraded to above 10% at CER, from prior high-single-digit growth guidance.
FY2026 Clean EBIT growth guidance raised to the high teens at CER.
BIO expects further revenue growth from tocilizumab launches and additional EBIT improvement through disciplined opex; CDMO full-year CER revenue outlook increased to slight growth.
AbbVie raised FY2026 Vraylar net sales guidance to USD 4.2bn.
- Pharma growth lifted clean EBIT, but FX losses and taxes cut net profit.RICHTER
Q4 2023 - Strong H1 2026 growth, innovation pipeline, and sustainability drive long-term value.RICHTER
Investor presentation - CER growth and upgraded EBIT guidance offset by FX-driven net profit decline.RICHTER
Q2 2026 - Q1 2026 saw 5.9% CER growth, 15% Clean EBIT rise, but FX and net profit declines.RICHTER
Q1 2026 - Strong 2025 results with robust growth in Women's Health and innovation, outlook remains positive.RICHTER
Q4 2025 - Revenue up 10.9–11%, Clean EBIT up 14.5–15.1%, but net profit down 13.2%.RICHTER
Q2 2025 - Acquisitions and innovation accelerate growth toward European leadership in women’s healthcare.RICHTER
Investor Update - Strong Q1 growth, record cash flow, and four biosimilar launches planned in next 12 months.RICHTER
Q1 2025 - Record 2024 growth and cash flow; 2025 targets 10% gains with cost and R&D focus.RICHTER
Q4 2024
)
)
)
)
)
)
)
)